linjc16/ctgov huggingface dataset:
Caudal Analgesia & Anticoagulated Patient

Study Overview
=================
Brief Summary
-----------------
Caudal analgesia is an effective intervention for lumbosacral pain. Some chronic pain patients take anticoagulants for vasculopathy treatment. Anticoagulation limits the use of caudal analgesia because of the risk of epidural bleeding. Caudal analgesia may be safe and effective in anticoagulated chronic pain patients. Quantitative analysis of prospective clinical data. Evaluation of caudal analgesia efficacy and safety in anticoagulated chronic pain patients. Analysis of outcome, and complications.

Detailed Description
-----------------
Caudal analgesia is an effective interventional therapy for chronic lumbosacral pain. Some chronic pain patients take anticoagulants for vasculopathy treatment. Anticoagulation limits the use of caudal analgesia because of the risk of epidural bleeding. Anticoagulation may be discontinued briefly, to allow caudal injection. Interruption of anticoagulation may be difficult and dangerous for some high-risk patients. Caudal analgesia may be safe and effective in anticoagulated chronic pain patients. Quantitative analysis of prospective clinical data. An evaluation of caudal analgesia safety in anticoagulated chronic pain patients. An analysis of treatment outcome, and complications.

Official Title
-----------------
Caudal Analgesia in Anticoagulated Chronic Pain Patients

Conditions
-----------------
Lumbar Pain Syndrome, Anticoagulants and Bleeding Disorders

Intervention / Treatment
-----------------
* Procedure: Caudal analgesia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult chronic pain patients who undergo caudal analgesia Exclusion Criteria: chronic pain patients who refuse caudal analgesia

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Caudal analgesia|Caudal analgesia for chronic lumbosacral pain|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain score, objective measurement using the validated Numeric Pain Rating scale | Pain score, using the Numeric Pain Rating scale of 0 to 10, low scores indicate less pain, high scores indicate worse pain | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Caudal analgesia
Mucosal Immunity: Influence on Infectious Viral Load: a Prospective Observational Study

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to learn about the influence of pre-existing mucosal immunity, i.e. antibodies and immune cells that are present at the nasal mucosa before infection, on the infectious viral load after infection with SARS-CoV-2 and influenza virus. We will include app 320 participants which will be followed for up to 17 months. We will monitor their nasal mucosal antibodies at regular intervals (once per month) and compare that to their infectious viral load if they are infected with SARS-CoV-2 and influenza virus.

Official Title
-----------------
Mucosal Immunity: Influence on Infectious Viral Load: a Prospective Observational Study

Conditions
-----------------
SARS-CoV-2 Infection, Influenza Viral Infections, Virus Shedding, Mucosal Immunity

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: In general good health, as determined by study investigators All participants must be living in the canton of Geneva or working/studying in the canton of Geneva and living in neighboring communities that are within one hour travelling distance by car. Exclusion Criteria: Inability to provide written consent. Severely immunocompromised subjects as determined by the study investigator Treated with inhaled drugs by nasal route within the last month

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No intervention|No intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SARS-CoV-2 infectious viral load |  | up to 14 days post symptom onset |
Choice of the Optimal Treatment Strategies for Mid-low REctal Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the efficacy, prognosis, health economics of different treatment modalities of mid-low rectal cancer in different centers in China, and to conduct cost utility analysis (CUA) on the treatment process of rectal cancer to explore the best treatment modality that meets the actual need of medical units in each region and at each level. The investigators hope to provide evidence-based medical suggestions for medical quality control of rectal cancer and revision of clinical guidelines, and provides a source of decision making for medical management and medical insurance.

Official Title
-----------------
Choice of the Optimal Treatment Strategies for Mid-low REctal Cancer-a National Multi-center, Prospective, Real World Study

Conditions
-----------------
Rectal Neoplasms

Intervention / Treatment
-----------------
* Other: Registry study, no specific intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pathologically confirmed rectal adenocarcinoma located within 12cm below the anal verge Exclusion Criteria: diagnosed with distant metastasis multiple primary colorectal cancers history of previous malignant tumors Pregnant or lactating women
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Registry study, no specific intervention|Registry study, no specific intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 3-year OS | 3-year overall survival | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 3-year DFS | 3-year disease-free survival | 3 years | 
| 3-year LR | 3-year local recurrence rate | 3 years | 
| 3-year distant metastasis rate | 3-year distant metastasis rate | 3 years | 
| neoadjuvant therapy rate | the percentage of patients who underwent standard neoadjuvant therapy | at the time point of surgery of the primary lesion | 
| adjuvant therapy rate | the percentage of patients who underwent standard adjuvant therapy | at the time point of 3-year follow up | 
| EUS/MRI assessment rate | the percentage of patients who underwent standard rectal EUS/MRI assessment | at the time point of surgery of the primary lesion | 
| R0 resection rate | the percentage of patients who underwent R0 resection | at the time point of surgery of the primary lesion | 
| CCR | Clinical Complete Response | immediately after the completion of neoadjuvant therapy assessment | 
| pCR | Pathologic Complete Response | immediately after the completion of surgery | 
| 30-day mortality | death occurring within 30 days of the surgery | 30 days after the surgery |
Comparative Effects of Motor Relearning Programme Versus Mirror Therapy on Balance and Gait in Chronic Stroke Patients

Study Overview
=================
Brief Summary
-----------------
To determine the effect of Motor Relearning Program versus Mirror Therapy for balance and gait in chronic ischemic stroke patients

Official Title
-----------------
Comparative Effects of Motor Relearning Programme Versus Mirror Therapy on Balance and Gait in Chronic Stroke Patients

Conditions
-----------------
Stroke

Intervention / Treatment
-----------------
* Diagnostic Test: Motor Relearning Program
* Diagnostic Test: Mirror Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • Chronic ischemic stroke of six or more than six months. Patients with age - 45- 65 years. Patients with good cognitive status i.e. 20 or more on MMSE.(Mini Mental Status Examination). Patients of both genders Patients with ambulation before stroke. Exclusion Criteria: • Patients who have musculoskeletal disorder impending lower limb function. Patient with any other Neurological disease. Patients have severe lower limb deformities, and vestibular disorders. Patients who have any joint disorder of lower limb. Patients who have any cardiac problem. Patients with history of recurrent stroke.

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Motor Relearning Program<br> | Diagnostic Test: Motor Relearning Program<br>* patients will receive Motor Relearning Program including static and dynamic sitting and standing balance while static sitting balance<br>|
| Other: Mirror Therapy<br> | Diagnostic Test: Mirror Therapy<br>* Mirror Therapy protocol. The baseline treatment will be weight bearing in standing which is extension of knee and weight bearing in standing on inclined<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mirror Therapy Techinique, Motor Relearning Programme Techinique |  | 6 Months |
The Impact of Standardized Tobacco Product Packaging on Young Adults in the Retail Environment

Study Overview
=================
Brief Summary
-----------------
The overall aim of this research is to experimentally evaluate the extent to which partially standardizing the color of tobacco packaging influences tobacco use intentions among young adults who have varying levels of tobacco use experience.

Official Title
-----------------
The Impact of Standardized Tobacco Product Packaging on Young Adults in the Retail Environment

Conditions
-----------------
Smoking, Cigarette

Intervention / Treatment
-----------------
* Behavioral: Package standardization


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ages 21-29 Past month cigarette smoker Exclusion Criteria: None.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 29 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Status Quo Packages<br>Cigarette packages appear as they normally do - no standardization | Behavioral: Package standardization<br>* Conditions vary in terms of amount of cigarette packages that are subject to standardization<br>|
| Experimental: Partial standardization<br>Cigarette packages appear with half of the package using a standardized color | Behavioral: Package standardization<br>* Conditions vary in terms of amount of cigarette packages that are subject to standardization<br>|
| Experimental: Full standardization<br>Cigarette packages appear with all of the packages fully standardized (by color and font) | Behavioral: Package standardization<br>* Conditions vary in terms of amount of cigarette packages that are subject to standardization<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quit smoking motivation | Motivation to quit smoking as assessed by the Motivation to Stop Scale (MTSS; Kotz et al., 2013; Drug and Alcohol Dependence) participants endorsing one of 7 items: I don't want to stop smoking. I think I should stop smoking but don't really want to. I want to stop smoking but haven't thought about when. I REALLY want to stop smoking but I don't know when I will. I want to stop smoking and hope to soon. I REALLY want to stop smoking and intend to in the next 3 months. I REALLY want to stop smoking and intend to in the next month. | Immediately after shopping in the RAND StoreLab |
Predictors of Sorafenib Response in HCC

Study Overview
=================
Brief Summary
-----------------
Evaluating the nutrition status of patients with advanced HCC who received sorafenib. Using the pretreatment nutrition status and quality of life as predictors to sorafenib response

Detailed Description
-----------------
This a cross sectional study will be conducted on 100 HCC treated with sorafenib Data were gathered from medical records, including age sex body weight and height (BMI) pre-therapy laboratory counts of white cells, neutrophils, lymphocytes, monocyte, hemoglobin and platelets; bilirubin, albumin and globulin concentration, AST, ALT, AFP, PT and CONC Barcelona Clinic Liver Cancer Stage (BCLC) of all patients The neutrophil-to- lymphocyte ratio (NLR) was calculated by dividing the neutrophil count by the lymphocyte count. The platelet- to-lymphocyte ratio (PLR) was calculated by dividing the platelet count by the lymphocyte count. Weight loss difference after treatment Portal hypertension was defined as presence of either collaterals on radiological examination, esophageal varices by upper gastrointestinal endoscopy and/or thrombocytopenia. Quality of life assessment. QoL was assessed using FACT Hepatobiliary Symptom Index (FHSI-8) Questionnaire. QoL was assessed at base line and 3-6 months after start of treatment.

Official Title
-----------------
Predictors of Sorafenib Response in Patients With Advanced Hepatocellular Carcinoma

Conditions
-----------------
Hepatocellular Carcinoma

Intervention / Treatment
-----------------
* Diagnostic Test: The neutrophil-to- lymphocyte ratio
* Diagnostic Test: Prognostic nutrition index


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HCC recieved sorafenib Exclusion Criteria: Patient refuse to participate Patients recieving other treatment modalities
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Hepatocellular carcinoma receiving sorafenib<br>Patient with advanced stage HCC receiving sorafenib | Diagnostic Test: The neutrophil-to- lymphocyte ratio<br>* It was calculated by dividing the neutrophil count by the lymphocyte count.<br>* Other names: NLR;Diagnostic Test: Prognostic nutrition index<br>* It was calculated using the following formula: serum albumin (g/L) + 0.005 × total lymphocyte count/μL<br>* Other names: PNI;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| assessment of nutrition status | Prognostic nutrition index | Augest 2023 to March 2024 | 
| Predictors of sorafenib response | The neutrophil-to- lymphocyte ratio | Augest 2023 to March 2024 | 
| Assess the quality of life | using FACT Hepatobiliary Symptom Index | Augest 2023 to March 2024 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nutrition assessment, Sorafenib, HCC
Clinical Significance of Occult Central Nervous System Localization

Study Overview
=================
Brief Summary
-----------------
In acute lymphoblastic leukemia (ALL), the occult central nervous system (CNS) involvement appears to be associated with poor prognosis. Flow cytometry (FCM) allows detection of occult CNS localization. The current international guidelines do not recommend the use of FCM in the assessment of CNS at onset in adult ALL patients. Large-scale prospective studies will help to clarify whether or not patients with occult CNS localization should undergo CNS-directed therapy. Understanding this seems particularly important nowadays considering that with the introduction of new drugs (monoclonal antibodies, next-generation tyrosine kinase inhibitors, CAR-T) the therapeutic approach of patients with ALS is increasingly chemo-free

Detailed Description
-----------------
The investigators propose a multicenter prospective study to evaluate the incidence of occult CNS localization and the impact of such localization on clinical outcome.Adult ALL patients routinely undergo diagnostic lumbar puncture (PL); cerebrospinal fluids (CSF )samples will be studied by investigation of conventional cytology (CC) and FCM at the time of the first and subsequent diagnostic PLs.

Official Title
-----------------
Clinical Significance of Occult Central Nervous System Localization in Adult Patients With Acute Lymphoblastic Leukemia. Prospective, Multicenter Study.

Conditions
-----------------
Acute Lymphoblastic Leukemia

Intervention / Treatment
-----------------
* Diagnostic Test: cerebrospinal fluids exams


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria. Patients aged more than18 years with diagnosis of ALL at onset undergoing diagnostic-therapeutic PL. Signed written informed consent in accordance with ICH/EU/GCP guidelines and national and local laws. Exclusion criteria. Patients <18 years of age Diagnosis other than ALL Inability to perform PL

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: cerebrospinal fluids exams|cerebrospinal fluids will be examined by conventional cytology and flow cytometry|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the incidence of occult CNS localization in adult patients with ALL |  | 36 months |
Phrenic Identification in the ICU

Study Overview
=================
Brief Summary
-----------------
This will be a prospective observational study where the investigator will scan patients' necks with an ultrasound and look for anatomical landmarks that may help identify the phrenic nerve.

Detailed Description
-----------------
Patients under protective mechanical ventilation, an intervention that saves lives, may need sedation and paralyzing agents. However, sedation and paralyzing agents are associated with multiple complications, including diaphragm dysfunction. Several strategies have been proposed to reduce diaphram dysfunction. A novel approach is to stimulate the phrenic nerve, either transvenously or transcutaneously. Transvenous stimulation requires a catheter, which eventually is associated with increased risk of infection and thrombosis. In this scenario, transcutaneous phrenic nerve pacing is attractive but may be more susceptible to patients' anthropometric measures. The correlation between patients' anthropometric measures and the location of the phrenic has been poorly studied.

Official Title
-----------------
Anatomical Landmarks for Identifying the Phrenic Nerve With Ultrasound in Intensive Care Unit

Conditions
-----------------
Ventilator Lung, Ventilator-Induced Lung Injury, Diaphragm Disease, Phrenic Nerve, Phrenic Nerve Stimulation, Neck Anatomy, Ultrasound

Intervention / Treatment
-----------------
* Procedure: Neck ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Age ≥ 18 years Admitted to ICU Exclusion Criteria Patients with a cervical spine collar Patients who refuse to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Neck ultrasound|The investigators will scan patients' necks with an ultrasound and look for anatomical landmarks to identify the phrenic nerve|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the number of participants where the investigators will successfully identify the phrenic nerve using only ultrasound and anatomical landmarks |  | 25-30 minutes | 
| To measure both phrenic nerves depth with an ultrasound in a heterogeneous population in the ICU |  | 25-30 minutes | 
| To measure the distance, in milimeters, between each phrenic nerve and other homolateral cervical structures such as the carotid artery and the jugular vein |  | 25-30 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To describe potential clinical and anthropometric variables associated with phrenic nerve depth |  | 25-30 minutes | 
| To assess how long it takes to find the phrenic nerve with ultrasound visualization. |  | 25-30 minutes |